Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation

References

• Abdulrazik M, Tamilvanan S, Khoury K, Benita S. (2001). Ocular delivery of cyclosporin A II. Effect of submicron emulsion’s surface charge on ocular distribution of topical cyclosporin A. STP Pharma Sci, 11, 427–432.
   Google Scholar
• Aksungur P, Demirbilek M, Denkbas EB, Vandervoort J, Ludwig A, Unlü N. (2011). Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J Control Release, 151, 286–294.
   PubMed Web of Science ®Google Scholar
• Barauskas J, Johnsson M, Tiberg F. (2005). Self-assembled lipid superstructures: Beyond vesicles and liposomes. Nano Lett, 5, 1615–1619.
   PubMed Web of Science ®Google Scholar
• Basaran E, Demirel M, Sirmagül B, Yazan Y. (2010). Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul, 27, 37–47.
   PubMed Web of Science ®Google Scholar
• BenEzra D, Maftzir G. (1990). Ocular penetration of cyclosporin A. The rabbit eye. Invest Ophthalmol Vis Sci, 31, 1362–1366.
   PubMed Web of Science ®Google Scholar
• Calvo P, Thomas C, Alonso MJ, Vilajato JL, Robinson JR. (1994). Study of the mechanism of interaction of poly(€-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. Int J Pharm, 103, 283–291.
   Web of Science ®Google Scholar
• De Campos AM, Sánchez A, Alonso MJ. (2001). Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm, 224, 159–168.
   PubMed Web of Science ®Google Scholar
• Dey S, Mitra AK. (2005). Transporters and receptors in ocular drug delivery: Opportunities and challenges. Expert Opin Drug Deliv, 2, 201–204.
   PubMedGoogle Scholar
• Di Venosa G, Hermida L, Batlle A, Fukuda H, Defain MV, Mamone L, Rodriguez L, MacRobert A, Casas A. (2008). Characterisation of liposomes containing aminolevulinic acid and derived esters. J Photochem Photobiol B, Biol, 92, 1–9.
   PubMed Web of Science ®Google Scholar
• el-Asrar AM, Tabbara KF, Geboes K, Missotten L, Desmet V. (1996). An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis. Am J Ophthalmol, 121, 156–161.
   PubMed Web of Science ®Google Scholar
• el Tayar N, Mark AE, Vallat P, Brunne RM, Testa B, van Gunsteren WF. (1993). Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: Evidence from partition coefficients and molecular dynamics simulations. J Med Chem, 36, 3757–3764.
   PubMed Web of Science ®Google Scholar
• Esposito E, Cortesi R, Drechsler M, Paccamiccio L, Mariani P, Contado C, Stellin E, Menegatti E, Bonina F, Puglia C. (2005). Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res, 22, 2163–2173.
   PubMed Web of Science ®Google Scholar
• Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X, Gan Y. (2010). Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm, 396, 179–187.
   PubMed Web of Science ®Google Scholar
• Ganesan V, Milford DV, Taylor CM, Hulton SA, Parvaresh S, Ramani P. (2002). Cyclosporin-related nephrotoxicity in children with nephrotic syndrome. Pediatr Nephrol, 17, 225–6; author reply 227.
   PubMed Web of Science ®Google Scholar
• Garg G, Saraf S, Saraf S. (2007). Cubosomes: An overview. Biol Pharm Bull, 30, 350–353.
   PubMed Web of Science ®Google Scholar
• Giorgione JR, Huang Z, Epand RM. (1998). Increased activation of protein kinase C with cubic phase lipid compared with liposomes. Biochemistry, 37, 2384–2392.
   PubMed Web of Science ®Google Scholar
• Gökçe EH, Sandri G, Egrilmez S, Bonferoni MC, Güneri T, Caramella C. (2009). Cyclosporine a-loaded solid lipid nanoparticles: Ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res, 34, 996–1003.
   PubMed Web of Science ®Google Scholar
• Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F, Wu W. (2011). Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine, 6, 965–974.
   PubMed Web of Science ®Google Scholar
• Han S, Shen JQ, Gan Y, Geng HM, Zhang XX, Zhu CL, Gan L. (2010). Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin, 31, 990–998.
   PubMed Web of Science ®Google Scholar
• Kachi S, Hirano K, Takesue Y, Miura M. (2000). Unusual corneal deposit after the topical use of cyclosporine as eyedrops. Am J Ophthalmol, 130, 667–669.
   PubMed Web of Science ®Google Scholar
• Kanai A, Alba RM, Takano T, Kobayashi C, Nakajima A, Kurihara K, Yokoyama T, Fukami M. (1989). The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc, 21, 3150–3152.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Smitha R. (2002). Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm, 28, 353–369.
   PubMed Web of Science ®Google Scholar
• Koevary SB. (2003). Pharmacokinetics of topical ocular drug delivery: Potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab, 4, 213–222.
   PubMed Web of Science ®Google Scholar
• Kuwano M, Ibuki H, Morikawa N, Ota A, Kawashima Y. (2002). Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm Res, 19, 108–111.
   PubMed Web of Science ®Google Scholar
• Lai J, Chen J, Lu Y, Sun J, Hu F, Yin Z, Wu W. (2009). Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS PharmSciTech, 10, 960–966.
   PubMed Web of Science ®Google Scholar
• Lai J, Lu Y, Yin Z, Hu F, Wu W. (2010). Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine, 5, 13–23.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. (2003). Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm, 56, 307–318.
   PubMed Web of Science ®Google Scholar
• Lang JC. (1995). Ocular drug-delivery conventional ocular formulations. Adv Drug Deliver Rev, 16, 39–43.
   Web of Science ®Google Scholar
• Larsson K. (1989). Cubic lipid-water phases: Structures and biomembrane aspects. J Phys Chem, 93, 7304–7314.
   Web of Science ®Google Scholar
• Mannermaa E, Vellonen KS, Urtti A. (2006). Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev, 58, 1136–1163.
   PubMed Web of Science ®Google Scholar
• Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. (1998). The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol, 49, 356–363.
   PubMed Web of Science ®Google Scholar
• Milani JK, Pleyer U, Dukes A, Chou HJ, Lutz S, Rückert D, Schmidt KH, Mondino BJ. (1993). Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology, 100, 890–896.
   PubMed Web of Science ®Google Scholar
• Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. (1996). Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res, 13, 163–167.
   PubMed Web of Science ®Google Scholar
• Ogiso T, Iwaki M, Paku T. (1995). Effect of various enhancers on transdermal penetration of indomethacin and urea, and relationship between penetration parameters and enhancement factors. J Pharm Sci, 84, 482–488.
   PubMed Web of Science ®Google Scholar
• Olivero DK, Davidson MG, English RV, Nasisse MP, Jamieson VE, Gerig TM. (1991). Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc, 199, 1039–1042.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. (2000). Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology, 107, 631–639.
   PubMed Web of Science ®Google Scholar
• Suhonen P, Järvinen T, Koivisto S, Urtti A. (1998). Different effects of pH on the permeation of pilocarpine and pilocarpine prodrugs across the isolated rabbit cornea. Eur J Pharm Sci, 6, 169–176.
   PubMed Web of Science ®Google Scholar
• Williams DL. (1997). A comparative approach to topical cyclosporine therapy. Eye (Lond), 11 (Pt 4), 453–464.
   PubMedGoogle Scholar
• Yang D, Armitage B, Marder SR. (2004). Cubic liquid-crystalline nanoparticles. Angew Chem Int Ed Engl, 43, 4402–4409.
   PubMed Web of Science ®Google Scholar